[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) officer Michael R. Megna reported changes in beneficial ownership on 10/04/2025. The filing shows 175 restricted share units (RSUs) granted (transaction code M) that convert into Class A ordinary shares and vest over four years with 25% vesting each anniversary of the grant date of 10/04/2021. The reporting person also recorded a sale of 85 Class A ordinary shares (transaction code F) at $38.49, leaving 38,101 shares owned after the sale. Following the RSU grant, total beneficial ownership is reported as 38,186 shares. The form was signed by an attorney-in-fact on 10/08/2025.

Insights

Corporate Governance Analyst

Officer received time‑vested RSUs and completed a small share sale the same day.

The reported 175 RSUs are standard long‑term compensation that vest 25% annually over four years from 10/04/2021, aligning the officer's interests with shareholders through future equity delivery. The filing also notes a contemporaneous disposal of 85 shares at $38.49, reducing direct holdings to 38,101 shares.

Governance risks are routine: the grant is subject to multi‑year vesting and the sale is an ordinary disposal; there are no indications of extraordinary transfers or derivative use. Monitor ongoing vesting anniversaries for incremental share increases and future Section 16 filings within typical reporting timeframes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	10/04/2025		M		175	A	(1)	38,186	D
Class A Ordinary Share	10/04/2025		F		85	D	$38.49	38,101	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	10/04/2025		M			175	(2)	(2)	Class A Ordinary Share	175	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.

	/s/ Douglas Barry, Attorney-in-Fact	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did KNSA officer Michael R. Megna report on Form 4?

The filing reports a grant of 175 RSUs and a sale of 85 Class A ordinary shares at $38.49 on 10/04/2025.

How many KNSA shares does Michael R. Megna beneficially own after these transactions?

The report shows 38,186 shares beneficially owned following the RSU grant and 38,101 shares following the sale; the filing lists 38,186 as the amount after the reported RSU acquisition and 38,101 after the sale.

What is the vesting schedule for the RSUs granted to the KNSA officer?

Each RSU vests over a four‑year period with 25% vesting on each anniversary of the grant date, which is 10/04/2021.

Were any derivative securities reported in this Form 4 for KNSA?

Yes. The grant is listed as restricted share units (RSUs) convertible into Class A ordinary shares; no exercisable derivatives or outstanding derivative holdings are reported after the transactions.

Who signed the Form 4 filing for Michael R. Megna and when?

The Form 4 was signed by an attorney‑in‑fact, Douglas Barry, on 10/08/2025.